ORCID Profile
0000-0001-7537-5462
Current Organisations
Weizmann Institute of Science
,
University of South Australia
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: WIT Press
Date: 20-09-2017
DOI: 10.2495/ESUS170481
Publisher: Elsevier BV
Date: 10-2011
Publisher: Elsevier BV
Date: 10-2021
Publisher: Elsevier BV
Date: 2019
Publisher: Elsevier BV
Date: 2016
Publisher: Elsevier BV
Date: 06-2021
Publisher: Elsevier
Date: 2018
Publisher: Author(s)
Date: 2016
DOI: 10.1063/1.4949127
Publisher: Elsevier BV
Date: 05-2012
Publisher: Elsevier BV
Date: 06-2018
Publisher: Informa UK Limited
Date: 08-02-2023
Publisher: Elsevier BV
Date: 05-2015
Publisher: Elsevier BV
Date: 05-2022
Publisher: Elsevier BV
Date: 05-2022
Publisher: Informa UK Limited
Date: 07-06-2022
Publisher: Elsevier BV
Date: 04-2019
Publisher: Frontiers Media SA
Date: 27-06-2022
DOI: 10.3389/FPSYT.2022.914668
Abstract: Attention deficit hyperactivity disorder (ADHD) frequently co-occurs with other neurodevelopmental diagnoses, such as autism spectrum disorder (autism), which can make clinical decision making around symptom management challenging for clinicians. There is a paucity of research examining pharmacotherapeutic management of children who have ADHD with co-occurring diagnoses. We aimed to report on the co-occurring diagnoses and symptom profile of children, and report on medication use, stratified by ADHD, autism and ADHD + autism diagnoses. Caregivers of 505 children (2–18 years) with ADHD ( n = 239), autism ( n = 117), and co-occurring ADHD + autism ( n = 149) completed a questionnaire on current medication use and clinical rating scales about their child's symptoms, as part of a broader project investigating diagnosis and management of symptoms in children with ADHD or autism. The parents of the ADHD group reported a higher proportion of their children had learning disorders (17.15%) and speech and language disorders (4.60%) compared to the parents of the autism and ADHD + autism groups. Parents of the ADHD + autism group reported higher proportions of intellectual disability (5.37%), oppositional defiant disorder (20.13%), anxiety (38.93%), depression (6.71%) and genetic conditions (3.36%) in their children, in comparison to the parents of the ADHD and autism groups. Children with ADHD were reported to be taking a higher proportion of psychotropic medication (90%), followed by ADHD + autism (86%) and autism (39%). The parents of children with ADHD + autism reported a higher proportion of non-stimulant ADHD medication (25.5%), antipsychotic (18.79%), antidepressant (22.15%) and melatonin (31.54%) use by their children, compared to the parents of the ADHD and autism groups. A similar proportion of children with ADHD + autism and ADHD were reported to be taking medication. However, the types of medication taken were different, as expected with reported co-occurring diagnoses. The complexity of symptoms and diagnoses in ADHD + autism warrants targeted research to optimize management and therapeutic outcomes.
Publisher: Author(s)
Date: 2018
DOI: 10.1063/1.5067109
Publisher: Elsevier BV
Date: 12-2021
Publisher: Author(s)
Date: 2017
DOI: 10.1063/1.4984441
Publisher: AIP Publishing
Date: 2020
DOI: 10.1063/5.0028728
Publisher: Elsevier BV
Date: 08-2015
Publisher: Wiley
Date: 17-08-2022
DOI: 10.1111/DMCN.15016
Abstract: In the field of disability research and advocacy, the notion of ‘cures’ is contentious. Cerebral palsy (CP) is no exception. In this narrative review, we combine perspectives gained during community consultation undertaken for the Australian and New Zealand Cerebral Palsy Strategy, 2020 with those published in the scientific and grey literature to understand whether ‘cures for CP’ is a reasonable and appropriate goal. We frame these perspectives through the lens of several ethical principles central to the discussion. These include maintaining hope while also being realistic, sensitivity to sharply different viewpoints amongst people with disability and their families, and responding to community priorities, societal attitudes, and identity. Through this exploration of the literature and perspectives, we arrived at a definition of ‘cures for CP’ that is pluralized and focuses on functional improvement and/or symptom reduction whilst still acknowledging the potential for neural repair/regeneration strategies.
Publisher: MDPI AG
Date: 10-09-2023
Publisher: Elsevier BV
Date: 04-2021
Publisher: Elsevier BV
Date: 08-2017
Publisher: Elsevier BV
Date: 08-2022
Publisher: Elsevier BV
Date: 11-2020
Publisher: Elsevier BV
Date: 03-2023
Publisher: Elsevier BV
Date: 04-2019
Publisher: Elsevier BV
Date: 12-2020
Publisher: Elsevier BV
Date: 08-2016
Publisher: Elsevier BV
Date: 02-2019
Publisher: AIP Publishing
Date: 2020
DOI: 10.1063/5.0030355
Publisher: Elsevier
Date: 2017
Publisher: AIP Publishing
Date: 2020
DOI: 10.1063/5.0028679
Publisher: Elsevier BV
Date: 11-2014
Publisher: Elsevier BV
Date: 02-2021
Publisher: Elsevier BV
Date: 04-2020
Publisher: Elsevier BV
Date: 2015
Publisher: Elsevier BV
Date: 09-2021
Publisher: MDPI AG
Date: 24-12-2022
DOI: 10.3390/EN16010189
Abstract: In the current study, a high temperature thermal storage system with a hybrid of phase change material and graphite as the storage materials is designed and evaluated as to its applicability for use as a utility-scale Carnot battery. The design includes an externally heated liquid sodium tank, which is used as the heat transfer fluid. This is used to charge and discharge the storage system consisting of a graphite storage medium sandwiched by two phase change materials. Finally, electrical generation is by way of a supercritical carbon dioxide Brayton cycle operated at 700 °C. Detailed modelling of these designs was conducted by way of a previously validated numerical model to predict performance metrics. Using the aforementioned designs, a preliminary cost estimate was undertaken to better determine applicability. From these results, it was found that while the graphite system was the most effective at storing energy, it was also the highest cost due to the high cost of graphite. In total, 18 storage tanks containing nearly 17,400 tons of storage material were required to store the 1200 MWht required to run the sCO2 power block for 10 h. Under the study conditions, the cost of a PCM-based Carnot battery was estimated to be $476/kWhe, comparable to other storage technologies. Furthermore, it was found that if the cost of the graphite and/or steel could be reduced, the cost of the system could be reduced to $321/kWhe.
Publisher: Elsevier BV
Date: 02-2021
Publisher: Elsevier BV
Date: 08-2022
Publisher: Elsevier BV
Date: 11-2011
Publisher: Informa UK Limited
Date: 07-09-2023
Publisher: Elsevier BV
Date: 06-2021
Publisher: Elsevier BV
Date: 11-2018
Publisher: Elsevier BV
Date: 03-2023
Publisher: Author(s)
Date: 2017
DOI: 10.1063/1.4984426
Publisher: Elsevier BV
Date: 11-2021
Publisher: Elsevier BV
Date: 05-2020
Publisher: Springer Science and Business Media LLC
Date: 17-12-2023
Publisher: Elsevier BV
Date: 12-2016
Publisher: Elsevier BV
Date: 04-2012
Publisher: AIP Publishing
Date: 2020
DOI: 10.1063/5.0028627
Publisher: American Chemical Society (ACS)
Date: 13-05-2021
Publisher: Elsevier BV
Date: 10-2017
Publisher: Elsevier BV
Date: 06-2022
Publisher: Elsevier BV
Date: 09-2012
Publisher: Elsevier
Date: 2014
Publisher: Elsevier BV
Date: 12-2020
Publisher: Elsevier BV
Date: 12-2019
Publisher: Elsevier BV
Date: 10-2022
Publisher: Elsevier BV
Date: 2021
Publisher: Elsevier BV
Date: 03-2014
Publisher: CRC Press
Date: 13-04-2022
Publisher: Elsevier BV
Date: 09-2021
Publisher: Springer Science and Business Media LLC
Date: 11-07-2016
Publisher: Elsevier BV
Date: 12-2016
Publisher: American Chemical Society (ACS)
Date: 14-06-2021
Publisher: Elsevier BV
Date: 2022
Publisher: Elsevier BV
Date: 09-2021
Publisher: Elsevier
Date: 2017
Publisher: Elsevier BV
Date: 03-2021
Publisher: Elsevier BV
Date: 2016
Publisher: Elsevier BV
Date: 06-2020
Publisher: Elsevier BV
Date: 08-2019
Publisher: Springer Science and Business Media LLC
Date: 05-08-2021
DOI: 10.1186/S13229-021-00457-3
Abstract: ASD and ADHD are prevalent neurodevelopmental disorders that frequently co-occur and have strong evidence for a degree of shared genetic aetiology. Behavioural and neurocognitive heterogeneity in ASD and ADHD has h ered attempts to map the underlying genetics and neurobiology, predict intervention response, and improve diagnostic accuracy. Moving away from categorical conceptualisations of psychopathology to a dimensional approach is anticipated to facilitate discovery of data-driven clusters and enhance our understanding of the neurobiological and genetic aetiology of these conditions. The Monash Autism-ADHD genetics and neurodevelopment (MAGNET) project is one of the first large-scale, family-based studies to take a truly transdiagnostic approach to ASD and ADHD. Using a comprehensive phenotyping protocol capturing dimensional traits central to ASD and ADHD, the MAGNET project aims to identify data-driven clusters across ADHD-ASD spectra using deep phenotyping of symptoms and behaviours investigate the degree of familiality for different dimensional ASD-ADHD phenotypes and clusters and map the neurocognitive, brain imaging, and genetic correlates of these data-driven symptom-based clusters. The MAGNET project will recruit 1,200 families with children who are either typically developing, or who display elevated ASD, ADHD, or ASD-ADHD traits, in addition to affected and unaffected biological siblings of probands, and parents. All children will be comprehensively phenotyped for behavioural symptoms, comorbidities, neurocognitive and neuroimaging traits and genetics. The MAGNET project will be the first large-scale family study to take a transdiagnostic approach to ASD-ADHD, utilising deep phenotyping across behavioural, neurocognitive, brain imaging and genetic measures.
Location: United States of America
Location: United States of America
No related grants have been discovered for Ming Liu.